These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 3296611)

  • 41. Increase in prevalence of leprosy caused by dapsone-resistant Mycobacterium leprae.
    Centers for Disease Control (CDC)
    MMWR Morb Mortal Wkly Rep; 1982 Jan; 30(52):637-8. PubMed ID: 6798411
    [No Abstract]   [Full Text] [Related]  

  • 42. The significance of dapsone (DDS)-resistant Mycobacterium leprae in untreated patients.
    Almeida JG; Chacko CJ; Christian M
    Int J Lepr Other Mycobact Dis; 1983 Sep; 51(3):374-7. PubMed ID: 6685700
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The sensitivity to Dapsone (DDS) of Mycobacterium leprae from patients with and without previous treatment.
    Shepard CC; Levy L; Fasal P
    Am J Trop Med Hyg; 1969 Mar; 18(2):258-63. PubMed ID: 4888029
    [No Abstract]   [Full Text] [Related]  

  • 44. Prevalence of drug resistance in Dharmapuri and A. Pallipatti areas of Tamil Nadu.
    Sreevatsa ; Ramu G; Desikan KV
    Indian J Lepr; 1985; 57(2):376-82. PubMed ID: 3908580
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Metabolic disposition of dapsone in patients with dapsone-resistant leprosy.
    Peters JH; Gordon GR; Levy L; Strokan MA; Jacobson RR; Enna CD; Kirchheimer WF
    Am J Trop Med Hyg; 1974 Mar; 23(2):222-30. PubMed ID: 4817667
    [No Abstract]   [Full Text] [Related]  

  • 46. Studies on sulfone resistance in leprosy. 3. A case of "partial" resistance.
    Pearson JM; Pettit JH; Rees RJ
    Int J Lepr Other Mycobact Dis; 1968; 36(2):171-8. PubMed ID: 4877115
    [No Abstract]   [Full Text] [Related]  

  • 47. Primary dapsone resistance in Bamako and Chingleput: final report; THELEP. Subcommittee on Clinical Trials of the Chemotherapy of Leprosy (THELEP) Scientific Working Group of the UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases.
    Lepr Rev; 1987 Sep; 58(3):209-18. PubMed ID: 3312895
    [No Abstract]   [Full Text] [Related]  

  • 48. Risk of paucibacillary leprosy patients released from control relapsing with multibacillary leprosy.
    Jesudasan K; Christian M
    Int J Lepr Other Mycobact Dis; 1985 Mar; 53(1):19-21. PubMed ID: 3998560
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dynamics of establishing resistance of M. leprae to dapsone and rifampicin in Martinique].
    Constant-Desportes-Relouzat M; Grosset J; Guelpalauras CC; Salvini B; Cales-Quist D
    Acta Leprol; 1986; 4(3):293-300. PubMed ID: 3551468
    [No Abstract]   [Full Text] [Related]  

  • 50. The contribution of "cure by dapsone monotherapy' to the reduction of prevalence of leprosy in the State of Orissa, India, 1983-1993.
    Patnaik PK; McDougall AC
    Indian J Lepr; 1996; 68(3):223-6. PubMed ID: 8889607
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Drug resistance in leprosy--a review.
    Ji BH
    Lepr Rev; 1985 Dec; 56(4):265-78. PubMed ID: 3908861
    [No Abstract]   [Full Text] [Related]  

  • 52. Dapsone drug resistance in the MDT era.
    Roche PW; Neupane KD; Failbus SS; Butlin CR
    Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
    [No Abstract]   [Full Text] [Related]  

  • 53. Recent advances in the study of the leprosy bacillus.
    Rees RJ
    Sci Basis Med Annu Rev; 1969; ():320-35. PubMed ID: 4917843
    [No Abstract]   [Full Text] [Related]  

  • 54. Does dapsone resistance really matter in the MDT era?
    Ji B
    Int J Lepr Other Mycobact Dis; 2001 Mar; 69(1):54-5. PubMed ID: 11480322
    [No Abstract]   [Full Text] [Related]  

  • 55. Co-incident (simultaneous) dapsone sensitivity and dapsone-resistant leprosy.
    Pettit JH
    Int J Lepr Other Mycobact Dis; 1983 Jun; 51(2):258-9. PubMed ID: 6684650
    [No Abstract]   [Full Text] [Related]  

  • 56. [Results of animal experimentation activities at the Institut Marchoux in Bamako (1982-1984)].
    Traore I; Nebout M
    Acta Leprol; 1985; 3(3):255-9. PubMed ID: 3909721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of the administration of B663 [G 30 320, Lamprene, clofazimine (Geigy)] on three groups of lepromatous and borderline of leprosy.
    Rodriguez JN; Abalos RM; Reich CV; Tolentino JG
    Int J Lepr Other Mycobact Dis; 1974; 42(3):276-88. PubMed ID: 4617715
    [No Abstract]   [Full Text] [Related]  

  • 58. Dapsone resistance in patients with treated lepromatous leprosy.
    Wheate HW
    Lepr Rev; 1979 Sep; 50(3):252-3. PubMed ID: 522601
    [No Abstract]   [Full Text] [Related]  

  • 59. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
    Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
    Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Primary dapsone resistance in leprosy.
    Vaishnavi C; Ganguly NK; Kumar B; Kaur S; Chakravarti RN
    Indian J Lepr; 1985; 57(3):507-13. PubMed ID: 3913705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.